Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone
Michael J. Levy(Mayo Clinic), Suresh T. Chari(The University of Texas MD Anderson Cancer Center), Prasad G. Iyer(Mayo Clinic), Steven R. Alberts(North Central Cancer Treatment Group), Barham K. Abu Dayyeh(Cedars-Sinai Medical Center), Naoki Takahashi(University of Fukui), Larissa L. Fujii‐Lau(University of Hawaii System), Felicity Enders(Mayo Clinic), Mark Topazian(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Joseph J. Larson(Mayo Clinic), Elizabeth Rajan(Mayo Clinic), William D. Mauck(Mayo Clinic), Randall K. Pearson(Mayo Clinic), Ferga C. Gleeson(Mayo Clinic), Bret T. Petersen(Mayo Clinic), Kristin C. Mara(Mayo Clinic), Kenneth K. Wang(Mayo Clinic in Arizona), Michael L. Kendrick, Santhi Swaroop Vege(Mayo Clinic)
Cited by 65
Related Papers
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
|The American Journal of Gastroenterology|2015|1.5k
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
|New England Journal of Medicine|2009|1.4k